LB Pharmaceuticals Inc. (LBRX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables effective brain receptor occupancy at much lower doses than amisulpride, supporting once-daily dosing and potentially fewer side effects. The main investment debate centers on whether the R-enantiomer's 5-HT7 activity delivers unique clinical benefits beyond D2/D3 antagonism, which remains unproven.
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 1-Year High – Here’s What Happened
LB Pharmaceuticals Inc (NASDAQ: LBRX - Get Free Report)'s stock price hit a new 52-week high during trading on Friday. The stock traded as high as $26.26 and last traded at $26.2950, with a volume of 47974 shares. The stock had previously closed at $24.94. Analyst Upgrades and Downgrades A number of equities analysts have
